Fluoride excess in coccidioidomycosis patients receiving long-term antifungal therapy: an assessment of currently available triazoles.

Abstract	The use of voriconazole, a trifluorinated antifungal, has been associated with the development of fluoride excess and periostitis/exostoses. We evaluated a cohort of patients on long-term triazole therapy and found that other fluorinated triazoles (fluconazole and posaconazole) conferred no risk for the development of hyperfluorosis and its complications in our cohort.
Authors	George R Thompson 3rd, Derek Bays, Stuart H Cohen, Demosthenes Pappagianis
Journal	Antimicrobial agents and chemotherapy (Antimicrob Agents Chemother) Vol. 56 Issue 1 Pg. 563-4 (Jan 2012) ISSN: 1098-6596 [Electronic] United States
PMID	22005993 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Chemical References	Antifungal Agents Pyrimidines Triazoles posaconazole Fluconazole Voriconazole Fluorides
Topics	Adolescent Adult Antifungal Agents (administration & dosage, adverse effects) Coccidioides (drug effects, growth & development) Coccidioidomycosis (drug therapy, microbiology) Cohort Studies Exostoses (chemically induced) Female Fluconazole (administration & dosage) Fluorides (metabolism) Humans Male Microbial Sensitivity Tests Middle Aged Periostitis (chemically induced) Pyrimidines (administration & dosage, adverse effects) Triazoles (administration & dosage, adverse effects) United States Voriconazole

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!